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Abstract
Background: It is very challenging for resource-limited settings to introduce universal health coverage (UHC),
particularly regarding the inclusion of high-cost renal dialysis as part of the UHC benefit package. This paper
addresses three issues: (1) whether a setting commits to include renal dialysis in its UHC benefit package and
if so, why and how; (2) how to ensure quality of renal dialysis services; and (3) how to improve the quality of
life of patients using psychosocial and community interventions.
Discussion: This article reviews experiences of renal dialysis programs in seven settings based on presentations and
discussions during the International Forum on Peritoneal Dialysis as a Priority Health Policy in Asia. A literature review
was conducted to verify and validate the data as well as to fill information gaps presented in the forum.
Five out of the seven settings implemented renal dialysis as part of their benefits package, while the other two
have pilots or programs in their nascent stage. Renal replacement therapy has become part of the universal
access package because these governments recognize the rising number of chronic kidney disease (CKD) cases,
the catastrophically high costs of treatment, and that this is the only life-saving treatment available to patients.
The recommendations are as follows: Governments should have a holistic approach to CKD interventions, including
primary prevention as well as psychosocial interventions. Governments should consider subsidizing CKD treatment
costs depending on their resources. Multi-stakeholder cooperation should be facilitated to enact these policies and
conduct research and development for all aspects of interventions. International collaboration should be
initiated to share experiences, good practices, and joint activities (e.g. capacity building and multinational
procurement of medical supplies).
Conclusion: This study provides practical recommendations to country governments as well as the international
community on how to meet the demand for good quality renal dialysis as part of UHC in resource-limited settings.
Keywords: Chronic kidney disease, End-stage renal disease, Low- and middle-income countries, Peritoneal dialysis,
Renal replacement therapy, Universal health coverage
Background
During the last decade, many low- and middle-income
countries (LMICs) declared major reforms in their
health systems to achieve universal health coverage
(UHC). Although UHC has been differently interpreted,
defined and translated into action [1], the ultimate goal
of such a policy as proposed by WHO is to promote
population health by ensuring universal access to essen-
tial healthcare of high quality, protecting people from
health impoverishment and improving equity in health
across socioeconomic groups [2]. In so doing, country
governments need to take into consideration three key
dimensions, namely the population to be covered as
beneficiaries, the services to be included in the benefit
package, and the proportion of public subsidization for
healthcare provision [3]. Following the World Health
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Assembly resolution on sustainable health financing for
UHC, the policy options to be adopted should be pertin-
ent to the economic, sociocultural and political context
of each country [4].
Every country which moves towards UHC has to raise
additional funds, either from domestic sources or from
international development support [3]. It is evident that,
in many LMICs, additional public resources have been
mobilized in order to guarantee access to the necessary
services for all people in need. For instance, in Thailand,
where a UHC scheme was established in 2002, govern-
ment spending on health has continued to grow, and a
significant increase of 75% was observed between 2005
and 2010 [5]. However, the demand for a higher level of
public health budget cannot be met in all countries, al-
though innovative financing mechanisms have already
been introduced. In particular, most resource-poor set-
tings have been facing a double burden of infectious dis-
eases and non-communicable diseases [6]. Some argue
that increasing access to healthcare can yield substantial
economic benefits in the macro and micro level, includ-
ing protecting households from illness-related catastro-
phe [2]. However, since it is usually difficult to link
economic growth with health investment, and since it
takes a long time to see economic contribution of health
initiatives, allocating a large amount of the already lim-
ited resources to UHC or even particularly expensive
health interventions is politically challenging [7].
Renal replacement therapy (RRT), including renal dia-
lysis and transplantation, for end-stage renal disease
(ESRD) is a high-cost, albeit life-saving service. On a glo-
bal level, it is estimated that 1 in every 20 people have
chronic kidney disease (CKD). ESRD – the last and most
critical stage of CKD – is a growing problem in most
countries. Its incidence is increasing globally at an an-
nual growth rate of 8% [8]. The 2014 United States
Renal Data System report shows that the incidence of
ESRD increased by 10% (per million population) from
2006 to 2012 in Korea, Malaysia, Mexico, Thailand, and
the USA [9]. People over 65 years of age are more vul-
nerable to CKD than those in other age groups, and also
have a higher probability of death [8]. The vascular and
systemic complications in this subpopulation does not
make them optimal candidates for renal transplantation,
and they are less likely to receive a kidney from a living
related donor. The costs for RRT are generally too high
for most patients in developing countries to afford [10].
Furthermore, kidney donor and transplantation services
are not widely available in resource-limited settings [11].
Liyanage et al. [12] estimated that, in 2010, around 2.3
million people died from lack of access to RRT, and
worldwide use of RRT will double from 2.6 million to
5.4 million people by 2030. Providing treatment for
ESRD patients is becoming more of a concern, especially
since most treatment options are costly and would need
to be balanced with provision of other health services.
Despite the notable budget implication of RRT, some
countries have made strides towards alleviating the bur-
dens for ESRD by subsidizing renal dialysis for their
people, with or without co-payment from households.
Besides the financial obstacle, inadequate infrastructure
and trained personnel are major supply-side barriers to
UHC of renal dialysis in resource-poor settings [10]. At
the same time, access and adherence to long-term health
services are hindered by factors of the demand side. For
renal dialysis, these include effective coverage, quality
and health outcomes of two major modalities, peritoneal
dialysis (PD) and haemodialysis (HD), which are associ-
ated with living circumstances, employment and educa-
tion of ESRD patients; support from family members
and community networks; and contextual elements such
as distance between patients’ residence and health facil-
ities and convenience in transportation [13, 14]. This
means that providing universal access to renal dialysis
requires not only public finance, but also suitable, inte-
grated measures to address all the impediments.
Based on presentations and discussion during the
International Forum on Peritoneal Dialysis as a Prior-
ity Health Policy in Asia, held in November 2014 in
Bangkok, this article reviews experiences of renal dia-
lysis programs in seven settings, namely Hong Kong,
Indonesia, Malaysia, the Philippines, Taiwan, Thailand,
and the United Kingdom. It emphasizes policy response to
the rising CKD burden, clinical innovations to ensure
quality of care, and psychosocial support provided by
paramedics, community, non-governmental organizations
and patient networks in each country context. The in-
formation gathered from personal communication to
the experts was part of the preparation of the work-
shop and was also taken into account. Additionally, a
literature review was conducted to verify and validate
as well as fill information gaps presented in the
forum. This paper will provide guidance to LMICs
committed to UHC on effective ways to respond to
the challenging issue of providing treatment to ESRD
patients. Table 1 illustrates country/setting profiles in
relation to their UHC policy and burden of CKD.
Review
Do countries committed to UHC implement renal dialysis?
Why and how?
Out of the seven study settings, five settings, including
the United Kingdom in the 1960s, Hong Kong in 1985
(PD-first policy) [15], Taiwan in 1995 [16], Malaysia in
2001 [17] and Thailand in 2008 [18], have implemented
universal access to renal dialysis. The Philippines issued
a national policy in 2014 for renal dialysis and imple-
mentation is in the early phase. For Indonesia, they have
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pilot programs and these are under consideration for in-
clusion in the benefit package. The governments of these
five settings (though not all) implemented this program,
which is the only life-saving treatment feasible for many
reasons. In the United Kingdom, both renal transplant-
ation and dialysis have been provided in the National
Health Service since the 1960s. By the end of 2013,
52%, 41.6% and 6.4% of the RRT patients in the
United Kingdom received a transplantation, HD and PD,
respectively [19]. In Hong Kong and Taiwan, despite
the capacity and financial resources to provide renal
transplantation, the majority of the population is Chinese
and hold a belief against organ donation [20–22].
Thailand and the Philippines do not have enough cap-
acity and financial resources to offer renal transplant-
ation. For instance, the limited supply of donated
kidneys [23], lack of infrastructure [10], and shortage of
specialized health professionals in the public sector [24]
are major barriers to transplantation. Although many
studies have demonstrated that renal transplantation is
more cost-effective compared to dialysis [25–27], these
studies have mostly focused on high-income countries
and therefore did not account for costs such as infra-
structure development and human resources. Further,
research [28, 29] showed that the estimated costs of
renal transplantations tend to be higher in the first few
years compared to dialysis, which could impact the
healthcare budget of developing countries more se-
verely compared to that of developed countries.
In this case, renal dialysis emerges as the most viable
option. Apart from being a life-saving treatment, paying
for dialysis is well-regarded as a common cause of cata-
strophic household health expenditure. It was docu-
mented that the annual cost of dialysis was 7–48 times
higher than the average income of populations in many
OECD countries [30]. This is one of the main reasons
that many governments decided to include dialysis in
their benefit packages.
Among the five countries that introduced access to
renal dialysis, each has a different policy regarding dialysis
modalities and may be divided into two groups. The first
group, Malaysia, Taiwan, and the United Kingdom, offers
choices for patients and providers to opt for HD or PD.
Patients have no incentive or disincentive to choose the
treatment they receive. However, HD is the more fre-
quently chosen dialysis modality, probably due to provider
financial incentives as it requires more frequent HD unit
visits, resulting in higher professional and HD unit fee
earnings. In these three settings, HD accounts for 88% in
Malaysia (versus 12% for PD), 91% in Taiwan (versus 9%
for PD), and 43% in the United Kingdom (versus 7% for
PD) [31–35]. On the contrary, the second group, Hong
Kong and Thailand, has instituted a policy on PD as the
first-line treatment through the creation of incentives for
provider and patient PD use. This includes full reimburse-
ment of PD and only reimburses HD for patients with
contraindications for PD. In Thailand, the UHC scheme
offers capital investment for PD providers, free training
for health professionals and infrastructure development.
Moreover, the Thai UHC scheme also allows health pro-
fessionals to receive a professional fee for providing PD
services. As a result, as of 2012, more than 70% of ESRD
patients in Hong Kong and 42% of new ESRD patients
under the UHC in Thailand now use PD as their treat-
ment [34, 36].
Experiences from Hong Kong [37] and Thailand [38]
demonstrate that PD has relatively lower cost for pro-
viders (including capital investment), less healthcare pro-
vider staff needed, and much lower travel time and cost
for patients, leading to increased patient autonomy and
satisfaction. This lower travel time and cost for patients
reflects the results of a study in South India indicating
that direct medical care costs for haemodialysis accounts
for only 55% of the total cost, whereas direct non-
medical costs, e.g. travel costs, account for around 20%
and indirect costs, e.g. opportunity cost loss from work,
account for 25% of the total cost [39]. The latter two
components make haemodialysis unaffordable by the
majority of the population even if dialysis is offered for
free. In Thailand, many rural hospitals have successfully
Table 1 Country/setting profiles for health systems and renal disease profiles
















renal disease, per million
population (2012) [9, 34]
Hong Kong Special
Administrative Region
1993 [60, 61] 7.2 38,123.5 5.1 [62] 99,200 1,192
Indonesia 2019 [63, 64] 249.9 3,475.3 3.0 58,100 265
Malaysia 1980s [65] 29.7 10,538.1 3.9 166,100 1,056
The Philippines 2016 [66, 67] 98.4 2,765.1 4.6 58,900 103
Taiwan (Chinese Taipei) 1995 [68] 23.4 [69] 20,924.9 [69] 6.6 [70] 99,200 2,902
Thailand 2002 [71] 67.0 5,779.0 3.9 84,500 906
The United Kingdom 1948 [72] 64.1 41,787.5 9.4 53,800 876
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implemented PD services for patients who are living in
remote areas (e.g. mountain villages) as patients have no
need to travel to health facilities often and can adminis-
ter the treatment themselves at home [40]. Nevertheless,
patients experience higher complications such as peri-
toneal infections due to poor education and those in low
socio-economic groups (though they may also have diffi-
culties accessing HD). Caregiver and patient burn-out is
also a challenge. HD, on the other hand, has advantages
as described by speakers from Malaysia, the Philippines
and Taiwan. For example, less patient responsibility and
higher provider comfort with the HD process. In the lit-
erature, authors found that HD offers better patient
socialization as they gather together in the HD units for
long periods of time [41].
In Indonesia and the Philippines, where the incidence
of ESRD and haemodialysis facilities have gradually been
increased simultaneously, RRT is categorized as a high-
cost treatment for ESRD. Most patients cannot afford
access to the treatment. Therefore, government health
insurance recently included RRT in their benefit pack-
age, though in practice, the effective coverage is limited.
For example, the cost of dialysis is partially supported
with certain co-payments that remain unaffordable for
the poor [42, 43]. The majority of patients in Asia re-
main unable to access RRT. It was estimated that the
gap between the actual number of patients undergoing
RRT and the estimated number of patients with ESRD is
very high. For example, in Indonesia, there are around
100,000 people who need RRT but do not have access to
the treatment [44].
PD and HD each have their advantages and disadvan-
tages (Table 2) [41, 45, 46]. While PD provides several
advantages in terms of clinical outcomes, government
treatment implementation, and patient uptake and ac-
cess, the selection of PD or HD will usually be based on
patient motivation, desire, geographic distance from an
HD unit, physician and/or nurse bias, patient education
and reimbursement policies [47]. Unfortunately, many
patients are not educated on PD before beginning dialy-
sis [48]. However, PD can improve patient survival in
the first few years, retain residual kidney function,
lower infection risk, and increase patient satisfaction
while reducing financial stress to governments by
addressing the burden of managing the growing num-
ber of ESRD patients [49].
The governments in Thailand and Hong Kong in-
troduced the PD first policy in order to ensure that
PD is promoted over HD based on the reasons stated
above. This policy can be seen as a limitation of free-
dom of patient choice. Nevertheless, it can be argued
that government priority is to ensure overall societal
benefit, and in these circumstances, the individual
benefit may not always be in line with society’s inter-
ests and choice may not be available to all [50]. For
example, if most patients are given the choice be-
tween PD and HD, the budget may be insufficient to
cover to the last patient or only patients in urban
areas are able to choose between PD and HD, while
patients in rural areas may receive only PD.
In conclusion, most settings committed to UHC im-
plemented universal access to renal dialysis because
renal dialysis is an essential service; it is life-saving
without a better alternative except transplantation, for
which efforts should continuously be made in order to
make donation and transplantation more widely avail-
able. Despite incurring a high cost and not representing
good value for money, the governments of these set-
tings consider that the inclusion of renal dialysis is
aligned with the objectives of UHC in terms of financial
protection. There may be several factors, such as geog-
raphy and political economy, which affect governments’
decisions to promote either dialysis modality. Experi-
ences from these five settings show that governments
contending with the following factors should opt for
PD as the first-line treatment: limited UHC budget allo-
cation for dialysis program, less human resources for
health, and geographical difficulties in healthcare facil-
ity access.
How to ensure quality of care
Clinical care for ESRD patients should be considered as
part of the integrated care for CKD patients. A holistic
approach to observe the progression of the disease since
the early stage should be taken into account. Healthcare
systems should be able to identify populations at risk of
CKD and CKD patients in the early stage of the disease
in order to provide appropriate care and support and
Table 2 Comparison of advantages and disadvantages of haemodialysis and peritoneal dialysis
Haemodialysis (in centre, hospital) Peritoneal dialysis
Advantages • Patient does not need to be taught to carry out treatment • Better survival rate within the first 1–2 years
• Social support system • Increased patient autonomy
• Applicable to a majority of patients • Lower cost
Disadvantages • Increased time and cost associated with transportation to the hospital • Patients must be disciplined about maintaining hygiene
• Increased risk of infection or complications • Technique failure may lead to infection or complications
• Potential burnout of patients or caregivers
Teerawattananon et al. Health Research Policy and Systems  (2016) 14:21 Page 4 of 8
delay disease progression [30]. Healthcare systems
should not only focus on investing in clinical care
for CKD patients, but there should also be more pri-
mary prevention efforts such as promoting a healthy
lifestyle (exercise and appropriate diet, e.g. salt and
sugar restriction). Experts from all settings had con-
sensus that primary healthcare is an instrumental
mechanism as they can reach the majority of the
population who are at risk. A study in Bhutan in-
formed that introducing universal access to the Package of
Essential Non-communicable disease interventions, in-
cluding population-based screening and early treat-
ment for diabetes and hypertension, offers very good
value for money [51].
All settings that participated in the forum established
a RRT registry, which is a database with information on
patients undertaking dialysis and/or kidney transplant-
ation. This database can track ESRD patients’ accessi-
bility to RRT by comparing the number of new patients
registered to the database to the estimated number of
patients based on epidemiological studies; assess quality
of RRT services through analysis of survival rates, rate
of developing complication(s) or switching between
modalities; and patient discontinuation of dialysis treat-
ment. Although the available databases in these settings
are at different levels of quality, they should also have
information on the socioeconomic status and geograph-
ical location of patients in addition to the medical in-
formation [52].
In addition, a financial mechanism should be devel-
oped to ensure that governments are investing in good
quality services and care for renal dialysis. In the
United Kingdom, the government developed renal-
specific quality indicators, such as blood pressure regu-
lation by angiotensin converting enzyme inhibitors or
angiotensin II receptor blocker drugs, and disease pro-
gression monitoring by measuring urine albumin and
creatinine ratio test [53]. The providers will have incen-
tives to provide this service because they are deemed to
be an important part of clinical care. There is strong
evidence linking angiotensin converting enzyme inhibi-
tors and angiotensin II receptor blocker drugs with the
delay of renal disease progression [54].
In Thailand, palliative care is delivered to ESRD pa-
tients who decide to receive palliative care instead of
the standard treatment of PD and HD, especially those
that are terminally ill or very old. In addition, some pa-
tients may have PD and HD for a certain period of time
and at some point decide to voluntarily withdraw from
treatment. It is important to note that palliative care
does not mean lack of care, but it is the provision of
medical, physical, and mental support to the patient
and their caregiver to ensure that patients at the ter-
minal stage receive humane care [55].
Improving quality of life of ESRD patients: everybody’s
business
CKD has been shown to negatively affect more than
just a patient’s physical state of health. It is important
to recognize the negative impact that a lifelong or long-
term illness has on a person’s quality of life. Depression
in patients with renal failure can be accompanied by
anxiety in associated partners, two of the most com-
mon psychological complications related to the disease.
To address CKD patients’ mental health, psychosocial
interventions have been put in place by the government
in health facilities, healthcare networks, and support
centres to improve quality of life. In Thailand, the
National Health Security Office has coordinated the
creation of networks and volunteer communities for
patients with chronic illness since 2003 to provide a
space for active volunteers to care for patients. Patient
support networks are available for a range of chronic
diseases, including renal disease, and these networks
work together and collaborate with healthcare profes-
sionals to operate a Friendship Support Center in order
to provide humanized healthcare [40].
However, the responsibility of ensuring good quality
of life for ESRD patients does not lie only with the
government – it is also a responsibility of NGOs, the
private sector, and communities. Not long after RRT
was included in the Thai UHC, Thailand Kidney
Friend Clubs were established to extend the Friend-
ship Support networks for CKD patients. The Clubs’
activities include providing information about kidney
disease and prevention, visiting homes of PD and HD
patients, protecting patient rights, and collaborating
with the National Health Security Office and Social
Security Office in developing the benefits package. In
the Philippines, dialysis solution companies also en-
deavour to improve patient outcomes and help them
cope with illness. For example, these companies also
raise awareness on the advantages of PD as a treat-
ment, such as the independence gained from having
home-based treatment, which offers a flexible sched-
ule, and maintaining the ability to work and travel.
They also work to promote patients’ optimism by or-
ganizing activities with partners across Asia such as
photo contests, sports competitions, walks, and travel-
ing with a PD train (in which the travellers dialyzed
while traveling).
Non-governmental efforts to improve patients’ quality
of life are not limited to support groups but also in-
clude financial support that helps alleviate the stress of
high cost RRT. In the Philippines, the Kidney Founda-
tion of the Philippines, a non-profit organization, runs
the Kidney Care Assistance Program, which provides fi-
nancial aid to patients on dialysis and transplant oper-
ation. Fundraising efforts for patients include an annual
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golf tournament for kidney care, public forums and in-
formation campaigns, correspondence to donors and
sponsors, media outlets, and kidney care walk-runs.
Conclusions
This paper addresses the challenges of tackling the in-
creased burden of CKD as part of the UHC policy.
Every government’s health ministry or related depart-
ment(s) should have concrete efforts to minimize in-
creasing incidence and clinical progression of CKD.
This can be done not just for CKD, but also overlap-
ping with efforts to deal with other diseases and health
risks such as hypertension, diabetes, cardiovascular dis-
ease, obesity and unhealthy lifestyles. Since treatment
of chronic kidney disease can have catastrophically high
costs for patients and their families, the governments
should consider programs that can subsidize CKD pa-
tients’ costs to a certain extent, depending on available
resources and meeting other competing priorities. As
the country’s situation changes, governments may re-
vise their policies as appropriate.
Financing, however, is not enough since CKD treat-
ment programs depend on other factors for their suc-
cess, including human resource development (including
more policy-oriented medical education), adequate sup-
ply and quality assurance. More research and develop-
ment for both the clinical and community/psychosocial
aspects are needed in order to ensure that the treat-
ment program meets patient needs. This includes creating
a patient treatment database. Finally, the government
should not be isolated in these efforts; involvement of
multiple stakeholders, such as medical associations, indus-
tries, civil societies, community groups and networks, and
family members, is encouraged.
At the international level, it is important to organize
regional forums that bring together not only academics
and medical professionals but also decision makers,
non-governmental organizations, paramedics and patient
group representatives, for sharing experiences, good
practices and problem-solving for policy implementa-
tion. It is also possible that each country’s national data-
base should follow a common regional platform to share
information and conduct monitoring and evaluation
across countries. These efforts pave the way for future
collaborations between countries, such as regional pro-
curement of dialysis solution for a more affordable and
reliable supply as well as joint capacity building activities
such as regional PD care training for practitioners, phy-
sicians, nurses and healthcare workers.
This study has some limitations. The review is select-
ive and not performed in a systematic manner; however,
it is based on priority issues discussed during the inter-
national forum. In addition, although the authors tried
to address the most important issues on renal dialysis
under the UHC program, financial models for funding
dialysis were not addressed in depth because since these
depend on several factors. Funding dialysis should be in
line with the financial model for UHC. Some countries,
for example the Philippines, have developed innovative
financial models using sin tax to fund dialysis and other
high-cost medical care, whereas Thailand pays for UHC
and dialysis from general tax.
Recommendations
1. Every government’s health ministry or related
department(s) should implement concrete efforts to
ensure a holistic approach for CKD including primary
prevention, especially to promote a healthy lifestyle,
screening and prompt treatment of diabetes and
hypertension. In addition, psychosocial interventions
should also be included in the holistic approach for
CKD patients in order to improve their quality of life.
2. Since treatment of CKD can have catastrophically
high costs for patients and their families, the
governments should consider programs that
subsidize CKD patients’ costs to a certain extent,
depending on available resources and meeting
other competing priorities. Financing, however, is
not enough because CKD treatment programs
need other factors for success such as human
resource development (including more policy-oriented
medical education), adequate supply and quality
assurance. PD First Policy can be considered the
policy choice for resource-finite countries committed
to UHC.
3. The government should not be isolated in these
efforts; involvement of multiple stakeholders, such
as medical associations, industries, civil societies,
community groups and networks, and family
members, is encouraged.
4. Governments and other stakeholders should support
research and development for both clinical and
community/psychosocial aspects in order to ensure
that the treatment program meets patient needs. This
includes creating a patient treatment database (e.g.
national registry) and community research.
5. Finally, international collaboration should be
initiated for sharing experiences, information and
good practices, joint capacity building activities,
and even multinational procurement of dialysis-related
commodities.
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